Waypoint Wealth Counsel’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$427K Sell
464
-314
-40% -$318K 0.22% 97
2025
Q4
$836K Buy
778
+59
+8% +$56.4K 0.31% 58
2025
Q3
$549K Buy
719
+90
+14% +$67K 0.22% 86
2025
Q2
$490K Sell
629
-163
-21% -$127K 0.24% 64
2025
Q1
$654K Buy
792
+161
+26% +$134K 0.41% 42
2024
Q4
$487K Sell
631
-17
-3% -$14.1K 0.32% 54
2024
Q3
$574K Buy
648
+107
+20% +$96.2K 0.39% 48
2024
Q2
$490K Buy
541
+8
+2% +$6.4K 0.37% 45
2024
Q1
$415K Buy
533
+31
+6% +$22.1K 0.32% 52
2023
Q4
$293K Buy
502
+20
+4% +$11.7K 0.25% 70
2023
Q3
$259K Buy
482
+3
+0.6% +$1.55K 0.24% 71
2023
Q2
$225K Buy
+479
New +$201K 0.2% 79

Other funds holding LLY

Waypoint Wealth Counsel's LLY Position: Q1 2026 in Review

Waypoint Wealth Counsel reduced its Eli Lilly (LLY) stake by 40% in Q1 2026, selling an estimated $318K and leaving 464 shares worth $427K. The position accounts for 0.22% of the portfolio, ranked #97.

Waypoint Wealth Counsel first reported a position in LLY in Q2 2023 and has held it in 12 quarters since. The position peaked at $836K in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Waypoint Wealth Counsel held 464 shares of Eli Lilly worth $427K as of Q1 2026.
  • Waypoint Wealth Counsel sold 314 Eli Lilly shares in Q1 2026, an estimated $318K.
  • Eli Lilly made up 0.22% of Waypoint Wealth Counsel's portfolio in Q1 2026, its #97 holding.
  • Waypoint Wealth Counsel first reported a position in Eli Lilly in Q2 2023 and has held it in 12 quarters since.
  • Waypoint Wealth Counsel's Eli Lilly position peaked at $836K in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Waypoint Wealth Counsel's 13F filing for Q1 2026, filed 23 Apr 2026.